Drug profile · INN
begelomab
BEGEDINA
begelomab (BEGEDINA) is a dipeptidyl peptidase iv inhibitor.
EMA: application withdrawn Antineoplastic and immunomodulating agents (L04) L04AA35
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — begelomab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
begelomab (BEGEDINA) is a dipeptidyl peptidase iv inhibitor.
Key facts
INN begelomab
Brand BEGEDINA
Mechanism Dipeptidyl peptidase IV inhibitor
Target Dipeptidyl peptidase 4
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AA35
Mechanism of action
Dipeptidyl peptidase IV inhibitor
Primary target: Dipeptidyl peptidase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is begelomab?
begelomab (BEGEDINA) is a dipeptidyl peptidase iv inhibitor.
What is the brand name for begelomab?
BEGEDINA is a marketed brand name for begelomab. Check FDA Drugs@FDA for the current US label holder and prescribing information.